Days After US Aflibercept Approval, Sandoz Is Hit By Regeneron Lawsuit

 
• By Dave Wallace

Days after Sandoz received US FDA approval for its Enzeevu aflibercept biosimilar, Regeneron sued alleging that Sandoz failed to follow the “patent dance” set out in the BPCIA framework and claiming infringement of multiple patents on its Eylea.

Eye with reflection of word "legal"
Regeneron said Sandoz has not followed the BPCIA’s “patent dance.” • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics